HEMATOPOIETIC STEM CELLS 2000: BASIC AND CLINICAL SCIENCES: Third International Conference
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 938:359-363 (2001)
© 2001 New York Academy of Sciences
Dendritic Cell-Based Vaccines in Patients with Hematological Malignancies
WOLFRAM BRUGGER,
ANYA SCHNEIDER,
THEODORA SCHAMMANN,
PATRICIA DILL,
FRANK GRÜNEBACH,
HANS-JÖRG BÜHRING,
LOTHAR KANZ AND
PETER BROSSART
University of Tübingen, Medical Center II, Department of Hematology, Oncology, Immunology, and Rheumatology, 72076 Tübingen, Germany
Address for correspondence: Wolfram Brugger, M.D., University of Tübingen, Medical Center, Dept. of Hematology, Oncology, Immunology, and Rheumatology, Otfried-Müller Str. 10, 72076 Tübingen, Germany. Voice: +49-7071-29-83698; fax: +49-7071-29-5591.
wolfram.brugger{at}med.uni-tuebingen.de
The epithelial mucin MUC1 is overexpressed on many epithelial malignancies as well as on some B-cell lymphomas and multiple myelomas. In the present study, we describe MUC1 expression also on primary AML blasts. To analyze the presentation of MUC1-derived HLA-A2 restricted peptides by primary AML blasts, we induced MUC1-specific cytotoxic T-lymphocytes (CTLs) in vitro using peptide pulsed dendritic cells from HLA-A2 + healthy donors as antigen-presenting cells. These CTLs efficiently lysed primary AML blasts that constitutively expressed both MUC1 and HLA-A2. The specificity of the CTLs was confirmed in a cold target inhibition assay. Our data demonstrate that MUC1-derived peptides are tumor antigens in AML which could potentially be used for immunotherapeutic approaches.
Key Words: MUC1 • AML • T-cell epitopes • Dendritic cells • Immunotherapy • Leukemia
| 
